Latest news with #StevenMadden
USA Today
3 days ago
- Business
- USA Today
A new Lululemon dress is stirring up the internet. Here's why
A new Lululemon dress is stirring up the internet. Here's why "Is this just for the label? Who walks into Lululemon and they're like, 'Oh my gosh, that's the cutest summer dress I've ever seen?'" TikTok creator Dasie said. Show Caption Hide Caption Steven Madden to buy UK-based luxury shoe brand Kurt Geiger The world of fashion footwear has a new pair, as shoe designer Steven Madden said it would buy UK-based luxury brand Kurt Geiger. The all-cash deal, valued at $360 million, expands Steve Madden's presence in international markets. The internet is going crazy over a new dress, and no, it is not "the dress" from 2015. Behind the hysteria is a multi-functional athleisure maxi skirt-dress duo from trendy sportswear brand Lululemon. Lululemon's new 2-in-1 Maxi Dress, a basic one-color dress that can be worn as an ankle-length maxi skirt or strapless dress, has garnered mixed emotions from social media users. Some believe the nearly $150 dress is worth every penny because of its versatility, enough that the dress is sold out in every size except extra large, and others think it's undeserving of the hype. Interested to hear what people think? Here's what the internet is saying about the viral Lululemon 2-in-1 Maxi Dress. Viral trends: 10 years later, 'the dress' still divides us. But we understand a lot more about why. How much does Lululemon's 2-in-1 Maxi Dress cost? The 2-in-1 Maxi Dress costs $148 on the Lululemon website, before shipping. As of June 3, the dress was sold out in every size and color but Light Ivory in extra large. However, shoppers can sign up to be notified if and when the dress will be restocked on the Lululemon website. What are people saying about the dress? In a TikTok video with 83,000 views as of June 3, content creator Chantalissa models the dress, which she encourages her followers to buy. "It takes a lot for me to buy something that I see on TikTok, but the second I saw this 2-in-1 dress from Lululemon, I literally went to the store instantly and tried it on," Chantalissa said in her video. "I actually feel like a princess in it. It's so beautiful, so flowy. I'm obsessed." On the flip side, content creator Dasie expressed her confusion about the dress's popularity, specifically because of the price and simple design. "Is this just for the label? Who walks into Lululemon and they're like, 'Oh my gosh, that's the cutest summer dress I've ever seen?'" Dasie said in a TikTok video with about 4,800 views as of June 3. "I'm not trying to be mean. No hate. You could walk into Walmart and get a cuter dress than that." To 'thneed' or not to 'thneed' Lululemon's 2-in-1 Maxi Dress quickly became deemed a "thneed" on social media. A "thneed" is a garment that can be worn multiple ways, and its name comes from the highly versatile object knitted by the Once-ler in Dr. Seuss' "The Lorax." As depicted in the original Lorax book and movie, a "thneed" can be used as a shirt, sock, glove, hat, carpet or pillow − "a fine thing that all people need." In addition to being multifunctional, a "thneed" is cheap ($3.98, as outlined in "The Lorax") and ethically sourced, as "thneeds" are made entirely from foliage of Truffula Trees, the circular and wispy trees in the story. While some may believe the 2-in-1 Maxi Dress is a "thneed," TikTok user Rachael, commonly known as "the Thneed Girl," disagrees. "The garment really isn't transforming at all. It's just going from being worn down at the hip to up at like the chest. It's really not transforming like a thneed really needs to do," Rachael said in a TikTok video. "You can love this dress. You can hate this dress. You can make whatever arguments you want about the ethics of this dress, Lululemon as a company, I really don't care, but it's not a thneed." Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@
Yahoo
4 days ago
- Business
- Yahoo
Genesco (GCO) Reports Q1: Everything You Need To Know Ahead Of Earnings
Footwear, apparel, and accessories retailer Genesco (NYSE:GCO) will be reporting results tomorrow morning. Here's what to expect. Genesco missed analysts' revenue expectations by 5% last quarter, reporting revenues of $745.9 million, flat year on year. It was a softer quarter for the company, with adjusted operating income in line with analysts' estimates. Is Genesco a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Genesco's revenue to grow 1.4% year on year to $463.8 million, a reversal from the 5.3% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$2.13 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Genesco has missed Wall Street's revenue estimates four times over the last two years. Looking at Genesco's peers in the footwear segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Steven Madden posted flat year-on-year revenue, missing analysts' expectations by 1%, and Crocs reported flat revenue, topping estimates by 3.1%. Steven Madden traded up 18.7% following the results while Crocs was also up 8.7%. Read our full analysis of Steven Madden's results here and Crocs's results here. There has been positive sentiment among investors in the footwear segment, with share prices up 3.9% on average over the last month. Genesco is up 5.3% during the same time and is heading into earnings with an average analyst price target of $23.50 (compared to the current share price of $21.31). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Caleres (CAL) Q1 Earnings: What To Expect
Footwear company Caleres (NYSE:CAL) will be reporting earnings tomorrow before market hours. Here's what to expect. Caleres missed analysts' revenue expectations by 1.1% last quarter, reporting revenues of $639.2 million, down 8.3% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and EPS guidance for next quarter missing analysts' expectations significantly. Is Caleres a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Caleres's revenue to decline 5.6% year on year to $622 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.37 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Looking at Caleres's peers in the footwear segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Steven Madden posted flat year-on-year revenue, missing analysts' expectations by 1%, and Crocs reported flat revenue, topping estimates by 3.1%. Steven Madden traded up 18.7% following the results while Crocs was also up 8.7%. Read our full analysis of Steven Madden's results here and Crocs's results here. There has been positive sentiment among investors in the footwear segment, with share prices up 8% on average over the last month. Caleres is up 16.1% during the same time and is heading into earnings with an average analyst price target of $20 (compared to the current share price of $18). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Health Catalyst, Steven Madden, Astronics, Wayfair, and Robinhood Shares Are Soaring, What You Need To Know
A number of stocks jumped in the pre-market session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Data Analytics company Health Catalyst (NASDAQ:HCAT) jumped 8.5%. Is now the time to buy Health Catalyst? Access our full analysis report here, it's free. Footwear company Steven Madden (NASDAQ:SHOO) jumped 5.1%. Is now the time to buy Steven Madden? Access our full analysis report here, it's free. Aerospace company Astronics (NASDAQ:ATRO) jumped 5.3%. Is now the time to buy Astronics? Access our full analysis report here, it's free. Online Retail company Wayfair (NYSE:W) jumped 8.4%. Is now the time to buy Wayfair? Access our full analysis report here, it's free. Financial Technology company Robinhood (NASDAQ:HOOD) jumped 5.2%. Is now the time to buy Robinhood? Access our full analysis report here, it's free. Health Catalyst's shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 10 months ago when the stock gained 40.1% on the news that the company reported strong second-quarter 2024 results that narrowly topped analysts' revenue expectations, while EPS beat by a more convincing margin. Adjusted EBITDA and free cash flow also beat Wall Street's estimates during the quarter. On the other hand, its revenue guidance for the next quarter missed analysts' expectations, and its gross margin shrank. Overall, this was a mixed, yet decent quarter for the company. Health Catalyst is down 48.7% since the beginning of the year, and at $3.76 per share, it is trading 58.3% below its 52-week high of $9.02 from December 2024. Investors who bought $1,000 worth of Health Catalyst's shares 5 years ago would now be looking at an investment worth $136.73. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
23-05-2025
- Business
- USA Today
Steve Madden challenges Adidas' trademark on stripes in new lawsuit
Steve Madden challenges Adidas' trademark on stripes in new lawsuit Show Caption Hide Caption Steven Madden to buy UK-based luxury shoe brand Kurt Geiger The world of fashion footwear has a new pair, as shoe designer Steven Madden said it would buy UK-based luxury brand Kurt Geiger. The all-cash deal, valued at $360 million, expands Steve Madden's presence in international markets. Adidas known for shoes with three parallel stripes, was sued on Wednesday by Steven Madden SHOO.O over its alleged effort to stop the American shoe company from selling fashion sneakers with two non-parallel bands. In a complaint filed in federal court in Brooklyn, New York, Steve Madden, as the company is often known, said it has grown "tired" of Adidas' decades of complaints about footwear whose designs bear no resemblance to its three-stripe design. These allegedly include objections to two Steve Madden sneakers launched this year: Viento, which has two bands, and Janos, whose two bands resemble the letter K. Steve Madden said Adidas' lawyers have demanded that Viento sales be halted because the design would likely confuse consumers, and signaled to the U.S. Patent and Trademark Office it may formally challenge the Janos design. "The use of band designs on footwear is ubiquitous in the fashion industry," Steve Madden said. "Simply put, Adidas does not own all stripes and should not be allowed to claim that it has a monopoly on all footwear that includes stripes, bars, bands or any shape having four sides — parallel, straight or not." More footwear news: Nike is releasing dirty Air Force 1s, social media is perplexed Adidas did not immediately respond to requests for comment outside business hours. Like some shoe companies including Nike NKE.N, Adidas sometimes turns to U.S. courts and agencies to stop rivals from selling products it considers knockoffs. Steve Madden, based in Long Island City, New York, said Adidas sued it twice in 2002 to challenge footwear with two parallel stripes and four parallel stripes, leading to a confidential settlement the next year. The latest dispute does not arise from that accord. Wednesday's lawsuit seeks a judgment that the Viento and Janos designs do not infringe Adidas' trademarks or three-stripe design, allowing Steve Madden to continue sales. The case is Steven Madden Ltd v Adidas AG et al, U.S. District Court, Eastern District of New York, No. 25-02847. Reporting by Jonathan Stempel in New York; Editing by Leslie Adler
